31.84
price up icon0.06%   0.02
after-market アフターアワーズ: 31.84
loading
前日終値:
$31.82
開ける:
$31.98
24時間の取引高:
788.06K
Relative Volume:
0.73
時価総額:
$1.89B
収益:
$66.05M
当期純損益:
$-422.60M
株価収益率:
-4.3911
EPS:
-7.251
ネットキャッシュフロー:
$-384.73M
1週間 パフォーマンス:
+13.15%
1か月 パフォーマンス:
+13.03%
6か月 パフォーマンス:
+22.04%
1年 パフォーマンス:
-10.94%
1日の値動き範囲:
Value
$31.30
$32.52
1週間の範囲:
Value
$27.70
$32.52
52週間の値動き範囲:
Value
$22.24
$46.00

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
名前
Agios Pharmaceuticals Inc
Name
セクター
Healthcare (1107)
Name
電話
617-649-8600
Name
住所
88 SIDNEY STREET, CAMBRIDGE, MA
Name
職員
540
Name
Twitter
@AgiosPharma
Name
次回の収益日
2026-07-30
Name
最新のSEC提出書
Name
AGIO's Discussions on Twitter

Compare AGIO vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
AGIO icon
AGIO
Agios Pharmaceuticals Inc
31.84 1.89B 66.05M -422.60M -384.73M -7.251
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
453.17 114.33B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
614.73 64.47B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
878.49 54.99B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
281.90 38.42B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
156.58 34.03B 742.00K -1.37B -1.07B -7.0731

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-20 繰り返されました H.C. Wainwright Buy
2025-11-24 開始されました Truist Buy
2025-11-20 アップグレード Leerink Partners Market Perform → Outperform
2025-11-19 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-02-24 開始されました H.C. Wainwright Buy
2024-10-16 開始されました Scotiabank Sector Outperform
2024-10-10 再開されました Raymond James Outperform
2024-09-27 ダウングレード Leerink Partners Outperform → Market Perform
2024-02-08 開始されました Cantor Fitzgerald Overweight
2023-02-03 開始されました Piper Sandler Overweight
2022-11-17 アップグレード Goldman Sell → Neutral
2022-07-27 アップグレード SVB Leerink Mkt Perform → Outperform
2021-12-03 開始されました BofA Securities Buy
2021-07-30 ダウングレード Goldman Neutral → Sell
2021-07-01 開始されました Raymond James Mkt Perform
2021-06-10 開始されました H.C. Wainwright Buy
2021-03-01 ダウングレード JP Morgan Overweight → Neutral
2021-03-01 アップグレード SVB Leerink Mkt Perform → Outperform
2021-02-26 ダウングレード SVB Leerink Outperform → Mkt Perform
2020-10-22 アップグレード Barclays Equal Weight → Overweight
2020-03-04 開始されました Barclays Equal Weight
2019-11-26 開始されました Cantor Fitzgerald Overweight
2019-09-23 アップグレード Guggenheim Neutral → Buy
2019-05-23 再開されました Goldman Neutral
2019-02-15 アップグレード SVB Leerink Mkt Perform → Outperform
2018-09-25 開始されました Leerink Partners Mkt Perform
2018-05-23 開始されました Citigroup Buy
2018-04-11 繰り返されました Credit Suisse Outperform
2018-02-15 繰り返されました Needham Buy
2018-02-15 繰り返されました SunTrust Buy
2017-09-15 開始されました RBC Capital Mkts Outperform
2017-08-10 繰り返されました Needham Buy
2017-08-08 繰り返されました SunTrust Buy
2017-08-02 アップグレード Leerink Partners Mkt Perform → Outperform
2017-06-26 ダウングレード Janney Buy → Neutral
2017-01-17 アップグレード Oppenheimer Perform → Outperform
2016-10-24 開始されました Needham Buy
2016-06-13 アップグレード JP Morgan Neutral → Overweight
2016-05-18 繰り返されました SunTrust Buy
すべてを表示

Agios Pharmaceuticals Inc (AGIO) 最新ニュース

pulisher
Jun 15, 2026

Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor EventSlideshow (NASDAQ:AGIO) 2026-06-15 - Seeking Alpha

Jun 15, 2026
pulisher
Jun 15, 2026

Agios to discontinue candidate for myelodysplastic syndromes - MSN

Jun 15, 2026
pulisher
Jun 14, 2026

Agios Pharmaceuticals (AGIO) Reports Promising Results from Phas - GuruFocus

Jun 14, 2026
pulisher
Jun 13, 2026

Agios Pharmaceuticals touts mitapivat gains despite sickle cell pain miss - MSN

Jun 13, 2026
pulisher
Jun 13, 2026

Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss - Yahoo Finance

Jun 13, 2026
pulisher
Jun 13, 2026

AGIO: Mitapivat shows durable efficacy in rare hematology, supporting growth and pipeline expansion - TradingView

Jun 13, 2026
pulisher
Jun 13, 2026

Technical Reactions to AGIO Trends in Macro Strategies - Stock Traders Daily

Jun 13, 2026
pulisher
Jun 13, 2026

Agios presents detailed mitapivat trial results for sickle cell - Investing.com UK

Jun 13, 2026
pulisher
Jun 13, 2026

Agios presents detailed mitapivat trial results for sickle cell By Investing.com - Investing.com Australia

Jun 13, 2026
pulisher
Jun 13, 2026

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease - The Manila Times

Jun 13, 2026
pulisher
Jun 13, 2026

Agios Pharmaceuticals Reports Positive Phase 3 Results for Mitapivat in Sickle Cell Disease, Highlighting Hemoglobin Response and Reduced Transfusion Burden - Quiver Quantitative

Jun 13, 2026
pulisher
Jun 13, 2026

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong ... - Caledonian Record

Jun 13, 2026
pulisher
Jun 13, 2026

Sickle cell patients needed fewer transfusions with Agios pill in Phase 3 - Stock Titan

Jun 13, 2026
pulisher
Jun 11, 2026

Agios Pharmaceuticals (NASDAQ:AGIO) Given New $31.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Jun 11, 2026
pulisher
Jun 11, 2026

J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Maintains Target Price $31 - Moomoo

Jun 11, 2026
pulisher
Jun 11, 2026

GW&K Investment Management LLC Purchases 354,359 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat

Jun 11, 2026
pulisher
Jun 10, 2026

J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Announces Target Price $31 - Moomoo

Jun 10, 2026
pulisher
Jun 10, 2026

Capital International Investors Buys New Position in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat

Jun 10, 2026
pulisher
Jun 10, 2026

Agios Pharmaceuticals, Inc. $AGIO Shares Bought by BNP Paribas Financial Markets - MarketBeat

Jun 10, 2026
pulisher
Jun 09, 2026

‘Disciplined’ $665M deal moves Oscotec’s cevidoplenib to Agios - BioWorld News

Jun 09, 2026
pulisher
Jun 09, 2026

Eyes on Asia: Olix, Agios, Eli Lilly - BioXconomy

Jun 09, 2026
pulisher
Jun 09, 2026

Analysts’ Top Healthcare Picks: McKesson (MCK), Agios Pharma (AGIO) - The Globe and Mail

Jun 09, 2026
pulisher
Jun 09, 2026

BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Jun 09, 2026
pulisher
Jun 08, 2026

Alpha Thalassemia Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Forma Therapeutics, Genmedicn Biopharma, Bristol-Myers Squibb, Agios Pharma - Barchart.com

Jun 08, 2026
pulisher
Jun 08, 2026

Erste Asset Management GmbH Acquires 40,000 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat

Jun 08, 2026
pulisher
Jun 07, 2026

The week in pharma: action, reaction and insight – week to June 5, 2026 - The Pharma Letter

Jun 07, 2026
pulisher
Jun 06, 2026

Why Agios Pharmaceuticals (AGIO) Is Down 5.4% After Overhauling Its Hematology PortfolioAnd What's Next - Sahm

Jun 06, 2026
pulisher
Jun 06, 2026

Agios Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo

Jun 06, 2026
pulisher
Jun 04, 2026

Q2 EPS Estimate for Agios Pharmaceuticals Reduced by Analyst - MarketBeat

Jun 04, 2026
pulisher
Jun 03, 2026

AGIO secures global rights to late-stage rare blood disorder candidate - MSN

Jun 03, 2026
pulisher
Jun 03, 2026

How The Tebapivat Setback Is Reframing The Story For Agios Pharmaceuticals (AGIO) - Yahoo Finance

Jun 03, 2026
pulisher
Jun 03, 2026

HC Wainwright Issues Optimistic Estimate for AGIO Earnings - MarketBeat

Jun 03, 2026
pulisher
Jun 02, 2026

AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate - The Globe and Mail

Jun 02, 2026
pulisher
Jun 02, 2026

Trading the Move, Not the Narrative: (AGIO) Edition - Stock Traders Daily

Jun 02, 2026
pulisher
Jun 02, 2026

Analysts Are Bullish on Top Healthcare Stocks: Agios Pharma (AGIO), Cogent Biosciences (COGT) - The Globe and Mail

Jun 02, 2026
pulisher
Jun 02, 2026

Agios inks global licensing agreement with Oscotec - The Pharma Letter

Jun 02, 2026
pulisher
Jun 01, 2026

Oscotec Signs Up to $665 Million Licensing Deal with Agios Pharmaceuticals for Autoimmune Drug Candidate Cevidoplenib - 알파경제

Jun 01, 2026
pulisher
Jun 01, 2026

Agios Halts Tebapivat Trials As Sickle Cell Focus Shapes Valuation - Sahm

Jun 01, 2026
pulisher
Jun 01, 2026

Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare HematologySlideshow (NASDAQ:AGIO) 2026-06-01 - Seeking Alpha

Jun 01, 2026
pulisher
Jun 01, 2026

Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib - Yahoo Finance

Jun 01, 2026
pulisher
Jun 01, 2026

Agios scraps blood cancer drug program after study miss - AOL.com

Jun 01, 2026
pulisher
Jun 01, 2026

AGIO Halts Tebapivat Development in Myelodysplastic Syndromes - The Globe and Mail

Jun 01, 2026
pulisher
Jun 01, 2026

AGIO: Cevidoplenib licensed for ITP, with strong phase II data and phase III planned for 2028 - TradingView

Jun 01, 2026
pulisher
Jun 01, 2026

Agios licenses oral SYK inhibitor for rare blood disorder By Investing.com - Investing.com South Africa

Jun 01, 2026
pulisher
Jun 01, 2026

Agios Pharmaceuticals (AGIO) Forms Licensing Deal for Cevidoplen - GuruFocus

Jun 01, 2026
pulisher
Jun 01, 2026

AGIO: Exclusive global license for cevidoplenib expands rare hematology pipeline and targets ITP - TradingView

Jun 01, 2026
pulisher
Jun 01, 2026

Agios licenses oral SYK inhibitor for rare blood disorder - Investing.com UK

Jun 01, 2026
pulisher
Jun 01, 2026

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib - The Manila Times

Jun 01, 2026
pulisher
Jun 01, 2026

Agios Pharmaceuticals Secures Exclusive Global Rights to Next-Generation SYK Inhibitor Cevidoplenib for Immune Thrombocytopenia Treatment - Quiver Quantitative

Jun 01, 2026
pulisher
Jun 01, 2026

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize ... - Caledonian Record

Jun 01, 2026
pulisher
Jun 01, 2026

Rare blood disorder drug deal gives Agios shot at $1B U.S. sales - Stock Titan

Jun 01, 2026

Agios Pharmaceuticals Inc (AGIO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Agios Pharmaceuticals Inc (AGIO) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Burns James William
Chief Legal Officer
Apr 02 '26
Sale
34.71
3,280
113,849
49,306
Gheuens Sarah
Chief Medical Officer
Apr 02 '26
Option Exercise
0.00
8,500
0
83,217
Gheuens Sarah
Chief Medical Officer
Apr 02 '26
Sale
34.71
2,940
102,047
80,277
Jones Cecilia
Chief Financial Officer
Apr 02 '26
Option Exercise
0.00
8,500
0
58,139
Jones Cecilia
Chief Financial Officer
Apr 02 '26
Sale
34.71
3,141
109,024
54,998
Milanova Tsveta
Chief Commercial Officer
Apr 02 '26
Option Exercise
0.00
8,500
0
50,091
Milanova Tsveta
Chief Commercial Officer
Apr 02 '26
Sale
34.71
3,262
113,224
46,829
Viswanadhan Krishnan
Chief Corp Dev & Strategy
Apr 02 '26
Option Exercise
0.00
8,100
0
13,241
Viswanadhan Krishnan
Chief Corp Dev & Strategy
Apr 02 '26
Sale
34.71
2,959
102,707
10,282
Goff Brian
Chief Executive Officer
Apr 02 '26
Option Exercise
0.00
39,028
0
191,104
$30.41
price up icon 1.27%
$55.40
price up icon 6.27%
$89.50
price down icon 1.43%
$54.21
price down icon 0.11%
ONC ONC
$263.92
price down icon 1.60%
$156.58
price down icon 2.17%
大文字化:     |  ボリューム (24 時間):